High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas.
Transl Oncol
; 14(4): 101038, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33596518
ABSTRACT
OBJECTIVE:
To determine the prognostic value of the preoperative Albumin-bilirubin (ALBI) score in high-grade glioma (HGG) patients.METHODS:
A retrospective study of 194 HGG patients was conducted. ROC analysis was used to determine the optimal cut-off value of ALBI score. Univariate and multivariate analysis was performed to identify prognostic factors associated with progression free survival (PFS) and overall survival (OS). The resulting prognostic models were externally validated by a demographic-matched cohort of 130 HGG patients.RESULTS:
Optimal cutoff value of ALBI score was -2.941. In training set, ALBI was correlated with age (Pâ¯=â¯0.001), tumor location (Pâ¯=â¯0.012) and adjuvant therapy (Pâ¯=â¯0.016). Both PFS (8.27â¯vs. 18.40 months, P<0.001) and OS (13.93â¯vs. 27.57 months, P<0.001) were significantly worse in the ALBI-high group. Strikingly, patients in ALBI-low group had 56% decrease in the risk of tumor progression and 57% decrease in the risk of death relative to high ALBI. Multivariate analysis further identified ALBI score as an independent predictor for both PFS (HR=0.47, 95% CI 0.34, 0.66) and OS (HR=0.45, 95% CI 0.32, 0.63). The ALBI score remained independent prognostic value in the validation set for both PFS (Pâ¯=â¯0.01) and OS (Pâ¯=â¯0.007). Patients with low ALBI score had better PFS and OS in all subgroups by tumor grade and treatment modalities.CONCLUSIONS:
The preoperative ALBI score is a noninvasive and valuable prognostic marker for HGG patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Transl Oncol
Ano de publicação:
2021
Tipo de documento:
Article